-
Journal Der Deutschen Dermatologischen... Mar 2022
Topics: Dermatology; Humans; Pathology, Molecular
PubMed: 35304963
DOI: 10.1111/ddg.14760 -
Current Gene Therapy Oct 2012Protein transduction domains (PTD) or cell penetrating peptides (CTPs) are small peptides able to carry proteins, peptides, nucleic acid, and nanoparticles, including... (Review)
Review
Protein transduction domains (PTD) or cell penetrating peptides (CTPs) are small peptides able to carry proteins, peptides, nucleic acid, and nanoparticles, including viral particles, across the cellular membranes into cells. In general, PTDs can be classified into 3 types: cationic peptides of 6-12 amino acids in length, comprised predominantly of arginine, ornithine and/or lysine residues; hydrophobic peptides such as leader sequences of secreted growth factors and cytokines; and cell-type specific peptides, identified by screening of peptide phage display libraries. These three types of transduction peptides have many different applications including delivery of therapeutic proteins and drugs, delivery of fluorescent or radioactive compounds for imaging, and improving uptake of DNA, RNA and even viral particles. Here we review the potential applications of protein transduction domains.
Topics: Animals; Cell-Penetrating Peptides; Drug Delivery Systems; Gene Transfer Techniques; Humans; Molecular Medicine; Oligopeptides; Optical Imaging; Organ Specificity; Protein Transport
PubMed: 22920684
DOI: 10.2174/156652312802762527 -
Journal of Molecular Medicine (Berlin,... Feb 2013
Topics: Adenosine; Animals; Humans; Molecular Medicine; Signal Transduction
PubMed: 23338058
DOI: 10.1007/s00109-013-0999-z -
Critical Reviews in Oncogenesis 2014Nanotechnology plays an increasingly important role not only in our everyday life (with all its benefits and dangers) but also in medicine. Nanoparticles are to date the... (Review)
Review
Nanotechnology plays an increasingly important role not only in our everyday life (with all its benefits and dangers) but also in medicine. Nanoparticles are to date the most intriguing option to deliver high concentrations of agents specifically and directly to cancer cells; therefore, a wide variety of these nanomaterials has been developed and explored. These span the range from simple nanoagents to sophisticated smart devices for drug delivery or imaging. Nanomaterials usually provide a large surface area, allowing for decoration with a large amount of moieties on the surface for either additional functionalities or targeting. Besides using particles solely for imaging purposes, they can also carry as a payload a therapeutic agent. If both are combined within the same particle, a theranostic agent is created. The sophistication of highly developed nanotechnology targeting approaches provides a promising means for many clinical implementations and can provide improved applications for otherwise suboptimal formulations. In this review we will explore nanotechnology both for imaging and therapy to provide a general overview of the field and its impact on cancer imaging and therapy.
Topics: Humans; Magnetic Resonance Imaging; Molecular Medicine; Nanoparticles; Nanotechnology; Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon
PubMed: 25271430
DOI: 10.1615/critrevoncog.2014011601 -
New Biotechnology Sep 2012This special issue of New Biotechnology is focused on molecular diagnostics and personalised medicine and appears at an epochal moment in the development of the field....
This special issue of New Biotechnology is focused on molecular diagnostics and personalised medicine and appears at an epochal moment in the development of the field. The practice of medicine is taking a significant and irrevocable turn towards personalisation, due to the great progress in areas such as genomics, pharmacogenomics and molecular diagnosis. It becomes increasingly apparent that to deliver the promise of personalised treatments, more and more novel medicines discovered today will be presented together with innovative companion diagnostics. The contributions to this volume touch on many disciplines, ranging from cell biology to genetics, immunology, molecular diagnostics, pharmaceutics and economic issues. The contributions of clinicians and basic scientists are synergistically presented to underline better the wide spectrum of studies that can contribute to the new field of personalised medicine. The promising perspectives of individualised treatments are related not only to higher effectiveness, but also to increased efficiency. This is relevant not only for the individual patient, but even more so for the general public, within a wider economical perspective where resources are limited and it becomes more and more mandatory to close the gap between social costs and benefits. This approach follows the steps of a stratified and individualised medicine and finds its final goal in an individualised healthcare.
Topics: Humans; Inventions; Pathology, Molecular; Precision Medicine
PubMed: 22504736
DOI: 10.1016/j.nbt.2012.03.010 -
The American Journal of Pathology Jul 2019The past decade has witnessed exponential growth in the generation of high-throughput human data across almost all known dimensions of biological systems. The discipline... (Review)
Review
The past decade has witnessed exponential growth in the generation of high-throughput human data across almost all known dimensions of biological systems. The discipline of network medicine has rapidly evolved in parallel, providing an unbiased, comprehensive biological framework through which to interrogate and integrate systematically these large-scale, multi-omic data to enhance our understanding of disease mechanisms and to design drugs that reflect a deep knowledge of molecular pathobiology. In this review, we discuss the key principles of network medicine and the human disease network and explore the latest applications of network medicine in this multi-omic era. We also highlight the current conceptual and technological challenges, which serve as exciting opportunities by which to improve and expand the network-based applications beyond the artificial boundaries of the current state of human pathobiology.
Topics: Humans; Pathology, Clinical; Pathology, Molecular
PubMed: 31014954
DOI: 10.1016/j.ajpath.2019.03.009 -
European Journal of Hospital Pharmacy :... Sep 2020
Topics: Clinical Competence; High-Throughput Nucleotide Sequencing; Humans; Medical Oncology; Molecular Medicine; Neoplasms; Workforce
PubMed: 32839254
DOI: 10.1136/ejhpharm-2019-002134 -
Journal of the Chinese Medical... Mar 2023
Topics: Prognosis; Pathology, Molecular; Risk Factors; Biomarkers, Tumor
PubMed: 36728438
DOI: 10.1097/JCMA.0000000000000872 -
Molecular Medicine (Cambridge, Mass.) Oct 2015
Topics: Achievement; History, 20th Century; History, 21st Century; Humans; Molecular Medicine; Periodicals as Topic
PubMed: 26605641
DOI: 10.2119/molmed.2015.00216 -
Histology and Histopathology Jun 2021Gastric cancer (GC) is the fifth most common cancer and the third cause of cancer-related deaths worldwide. In western countries, more than half of GC patients are... (Review)
Review
Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.
Gastric cancer (GC) is the fifth most common cancer and the third cause of cancer-related deaths worldwide. In western countries, more than half of GC patients are diagnosed at advanced stages and 5-year survival rates range between 20-30%. The only curative treatment is surgery, and despite recent advances in oncological therapies, GC prognosis is still poor. The main prognostic tool for patient categorization and treatment selection is the TNM classification, but its limitations are being increasingly recognized. Early recurrences may occur in early-stage disease, and patients at the same stage show heterogeneous outcomes. Thus, there is a need to improve GC stratification and to identify new prognostic factors, which may allow us to select drug-susceptible populations, refine patient grouping for clinical trials and discover new therapeutic targets. Molecular classifications have been developed, but they have not been translated to the clinical practice. On the other hand, histological assessment is cheap and widely available, and it is still a mainstay in the era of molecular medicine. Furthermore, histological features are acquiring new roles as reflectors of the genotype-phenotype correlation, and their potential impact on patient management is currently being analyzed. The aim of this literature review is to provide a modern overview of the histological assessment of GC. In this study, we discuss recent topics on the histological diagnosis of GC, focusing on the current role of Laurén classification and the potential value of new histological features in GC, such as inflammatory infiltration and tumor budding.
Topics: Cytodiagnosis; Humans; Inflammation; Molecular Medicine; Neoplasm Staging; Prognosis; Stomach Neoplasms; Survival Rate
PubMed: 33565601
DOI: 10.14670/HH-18-309